FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 317 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Feeding the Gut July 14, 2023 Color-Blind Groom Sees Color For First Time After Bride Surprises Him... November 9, 2021 ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February January 18, 2022 Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... February 25, 2025 Load more HOT NEWS FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press... Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults
